BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15543617)

  • 1. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
    Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
    Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
    Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
    Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
    Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
    Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
    Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
    Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
    Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
    Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
    Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
    Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
    Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
    Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint.
    Boersma-Vreugdenhil GR; Kuipers J; Van Stralen E; Peeters T; Michaux L; Hagemeijer A; Pearson PL; Clevers HC; Bast BJ
    Br J Haematol; 2004 Aug; 126(3):355-63. PubMed ID: 15257707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
    Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
    Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
    Intini D; Fabris S; Storlazzi T; Otsuki T; Ciceri G; Verdelli D; Lombardi L; Rocchi M; Neri A
    Br J Haematol; 2004 Aug; 126(3):437-9. PubMed ID: 15257719
    [No Abstract]   [Full Text] [Related]  

  • 16. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
    Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
    Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
    Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
    Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular study of the t(4;14) in multiple myeloma.
    Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
    Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
    Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
    Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
    Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.